Great content and very well attended by industry experts

President, AgilePV

 

Amsterdam, 10 - 11 September 2018

Schedule

Create your personal agenda –check the favourite icon

Sep 1008:50
Conference pass
Sep 1009:00
Conference pass
Sep 1009:20
Conference pass

Global Clinical Trials and the complexities of Reference Safety Information (RSI)

Keynotes
  • Overview of the changing landscape related to RSI
  • Perspectives on navigating RSI complexities in light of new EU requirements
  • Potential approaches for consideration in context of global clinical trial conduct
Sep 1009:40
Conference pass

Developments in drug safety for biologics

Keynotes
Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, G.S.K BiologicalsBelgium
Sep 1011:20
Conference pass

Can PV Keep up with the Pace of Innovation? Exploring the Rapid Evolution of AI in Pharmacovigilance

Keynotes
  • AI for case processing
  • AI applied to signal detection
  • Regulatory considerations
Bruce Palsulich, Vice President Safety Product Strategy, Oracle Health SciencesUnited States
Sep 1011:40
Conference pass

Roundtables

Keynotes
Achieving effective service provider management
Ricarda Tiemeyer, Head of Drug Safety, Roche Pharmaceuticals SaSwitzerland
AI and big data in drug safety
Nina Jeliazkova, Technical Manager, Idea ConsultingBulgaria
Mark Cronin, Professor of Predictive Toxicology, Liverpool John Moores UniversityUnited Kingdom
Romualdo Beningni, Consultant, alpha-pretoxItaly
Are post-marketing questionnaires valuable?
Fernando Solimando, Senior Risk Management Physician, Boehringer IngelheimGermany
Brexit: Where next?
David Jefferys, Senior Vice President, Eisai Medical ResearchUnited Kingdom
Different approaches - signal detection for small to medium companies
Examining the challenges of updating risk management plans in line with revision II of GVP V
Liana Gross Martirosyan, Senior Pharmacovigilance Assessor, Dutch Medicines Evaluation BoardNetherlands
Examining the Pharmacovigilance System Masterfile and licensing pharma audit
Monika Manske, Associate Director of Global Pharmacovigilance Governance, MylanGermany
How to manage a pharmacovigilance crisis in the XXI century?
Improving local drug safety processes
Miroslava Novakova, DSM, G.S.K.Slovakia
Outsourcing in PV
Katrien Soleme, Senior Compliance Specialist, Global Quality Regulatory Compliance & Clinical Trials & Safety, Bristol Myers SquibbBelgium
Pharmacovigilance in China
Kevin Burke, Senior Case Management Lead, CSL BehringAustralia
Elva Xu, Associate Director, Medical Affairs and Pharmacovigilance, CSL BehringChina
PV considerations in market research and patient support programs
Reduction of avoidable medical related harm
Jayne Lawrence, Head of Division of Pharmacy and Optometry, University of ManchesterUnited Kingdom
Sunayana Shah, Head of regulatory and safety policy, Association of the British Pharmaceutical IndustryUnited Kingdom
The new eudravigilance: process changes and best practices
Maria Maddalena Lino, Terapeutic Area Safety Head, SeqirusItaly
Francesco Tescione, EU Qualified Person for Pharmacovigilance QPPV, Molteni FarmaceuticiItaly
Sep 1013:30
Conference pass

Chair’s remarks

Signal Detection & Management and Safety in Medical Devices
Sep 1013:30
Conference pass

Chair’s remarks

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Emanuel Lohrmann, Lead Risk Management Physician, Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Sep 1013:30
Conference pass

Chair’s remarks

Big Data and AI in Safety, Regulation and Case Processing
Howard Snow, Vice President of Drug Safety and Epidemiology, Novartis International AGSwitzerland
Sep 1013:30
Conference pass

Chair’s remarks

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Celine Adessi, Safety Science Senior Group Director pRED Oncology, RocheSwitzerland
Sep 1013:35
Conference pass

Latest developments in signal management

Signal Detection & Management and Safety in Medical Devices
Mircea Ciuca, Head of Medical and Clinical Drug Safety, Vifor PharmaSwitzerland
Sep 1013:35
Conference pass

Developments in innovative technology for drug safety

Big Data and AI in Safety, Regulation and Case Processing
Salvatore Giorgio Cicirello, Senior Director Pharmacovigilance Innovation, Global Drug Safety & Risk Management, CelgeneSwitzerland
Sep 1013:35
Conference pass

“Orphanizing” NSCLC: Subsetting for more targeted, more effective and less toxic therapies: EGFR and ALK

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
  • Chemotherapy for NSCLC
  • NSCLC subsets (EGFR and ALK)
  • Targeted therapy for NSCLC subsets: efficacy, toxicity, class effects
Dennis Vargo, Global Safety Lead, Takeda Pharmaceutical CompanyUnited States
Sep 1013:55
Conference pass

Pharmacogenomics in Post-Marketing Pharmacovigilance

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Sep 1013:55
Conference pass

Precision Pharmacovigilance: Is this the way forward?

Big Data and AI in Safety, Regulation and Case Processing
Vivek Ahuja, Vice President of Global Pharmacovigilance, ArisGlobalIndia
Sep 1014:15
Conference pass

Employing quantitative tools to support signal detection

Signal Detection & Management and Safety in Medical Devices
Christina Virkelyst Tvermoes, Head PV Science, LEO PharmaDenmark
Sep 1014:15
Conference pass

A Merck Case Study into risk management

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Matthias Boedding, Senior Director, Merck GroupGermany
Sep 1014:15
Conference pass

Latest developments for global standards on safety in oncology

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Fatima Yousef, Head Of Quality and Medication Safety unit, King Abdullah International Medical Research Center KAIMRCSaudi Arabia
Sep 1014:35
Conference pass

Working with vendor providers to support signal detection capabilities

Signal Detection & Management and Safety in Medical Devices
Simon Ashworth, VP, EU Qualified Person for Pharmacovigilance (QPPV) and Head EU Compliance and Marketed Products, Takeda Development Centre EuropeUnited Kingdom
Sep 1014:35
Conference pass

Delivering Differentiated Outcomes in PV Operations

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Anand Kiran, Co-Founder, EVP – Global Operations and Medical Solutions, IndegeneIndia
Sep 1014:35
Conference pass

Automation in case handling activities

Big Data and AI in Safety, Regulation and Case Processing
Andrew Finlay, Pharmacovigilance Excellence Principal, AstraZenecaUnited Kingdom
Sep 1014:35
Conference pass

Nature of drug safety work in the pre-clinical/clinical transition and early clinical development phase

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Steffen Ernst, Senior Safety Medical Director CVMD, AstraZenecaUnited Kingdom
Sep 1015:25
Conference pass

Chair’s remarks

Signal Detection & Management and Safety in Medical Devices
Sep 1015:25
Conference pass

Chair’s remarks

Big Data and AI in Safety, Regulation and Case Processing
Sep 1015:25
Conference pass

Chair’s remarks

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Jorgen Matz, Head of Global Pharmacovigilance and Drug Safety, Insud PharmaSpain
Sep 1015:30
Conference pass

Predictive Signaling

Signal Detection & Management and Safety in Medical Devices
Saeed Amin, Director, Global Head Safety Data Management, US Head Global Pharmacovigilance Compliance & Business Management, OtsukaUnited States
Sep 1015:30
Conference pass

Using informatics within a global standardized environment

Big Data and AI in Safety, Regulation and Case Processing
Elena Davison, Director of Global Pharmacovigilance Informatics, Sunovion PharmaceuticalsUnited States
Sep 1015:50
Conference pass

Beyond signal detection – new innovations using molecular analysis of adverse event data

Signal Detection & Management and Safety in Medical Devices
David Jackson, Phd, Chief Innovation Officer, Molecular HealthGermany
Sep 1015:50
Conference pass

Balancing the benefits and burdens of local literature monitoring

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Daniela Ranzani, AdisInsight Product Manager, Pharmacovigilance, Europe, The Middle East And Africa, Springer NatureItaly
Sep 1016:10
Conference pass

The role of risk management within signal detection

Signal Detection & Management and Safety in Medical Devices
Marcus Schartau, Safety Surveillance Risk Management Specialist, Safety Surveillance, Novo Nordisk A/SDenmark
Sep 1016:10
Conference pass

Evaluating the effectiveness of risk minimization activities

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Sep 1016:10
Conference pass

Utilizing Big Data to make benefit-risk decisions

Big Data and AI in Safety, Regulation and Case Processing
  • What is Big Data?
  • Methods to effectively leverage Big-Data in Safety
  • The role of Big Data for Benefit-Risk decision making
Priya Singhal, Global Head, Senior Vice President, Safety and Benefit Risk, BiogenUnited States
Sep 1016:10
Conference pass

Ensuring quality oversight in PV vendor management

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Keya Pitts, Global Head of PV Q/A, AstellasUnited States
Sep 1016:30
Conference pass

Signal detection for innovative and generic products in a mid-sized company

Signal Detection & Management and Safety in Medical Devices
Fabian Heisig, Head Of Safety, Benefit Risk And Global Drug Safety, GrunenthalGermany
Sep 1016:30
Conference pass

Effectiveness of complex additional risk minimization measures – A success story

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Amgad Shebl, Director of Global Clinical Safety and Pharmacovigilance, CSL BehringGermany
Sep 1016:30
Conference pass

Innovation in benefit-risk evaluation present and future

Big Data and AI in Safety, Regulation and Case Processing
  • Among Regulators, HTAs, industry and academia, Benefit-Risk evaluation has shifted into a more structured and quantitative approach
  • The role of patient preference in the medicinal product decision-making, including Benefit-Risk evaluation, has significantly increased
  • Given this shift, various innovative methods of quantitative Benefit-Risk evaluation and patient-preferences have been evaluated in various public-private initiatives
Stephanie Tcherny Lessenot, Global Head of Benefit-Risk Evaluation, SanofiFrance
Sep 1016:30
Conference pass

Implementing effective standards in PV outsourcing

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Bert Van Leeuwen, deputy QPPV, Astellas Pharma Europe BVNetherlands
Sep 1017:20
Conference pass

Chair's remarks

Signal Detection & Management and Safety in Medical Devices
Sep 1017:20
Conference pass

Chair’s remarks

Big Data and AI in Safety, Regulation and Case Processing
Paul Wang, Director, Pv Science, Gilead/KiteUnited States
Sep 1017:20
Conference pass

Chair’s remarks

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Marco Sardella, Chief Pharmacovigilance Officer and Q.P.P.V. for Europe, AdienneItaly
Sep 1017:25
Conference pass

Risk management for established products and outsourcing functions

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Nicole Baker, EEA QPPV, Head of Global Pharmacovigilance, Besins HealthcareUnited States
Sep 1017:25
Conference pass

TBC

Big Data and AI in Safety, Regulation and Case Processing
Peter Verdru, Vice President and Head of Patient Safety, UCB Pharma ltdUnited Kingdom
Sep 1017:25
Conference pass

Safety measures in CAR T and Cellular Therapy

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
David Chonzi, VP, Patient Safety and Risk Management, Kite, A Gilead CompanyUnited Kingdom
Sep 1017:45
Conference pass

Risk management for advanced therapies

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Haris Shaikh, Senior Director Pharmacovigilance, Orchard TherapeuticsUnited Kingdom
Sep 1017:45
Conference pass

Artificial Intelligence and Literature Monitoring for Drug Safety—What the future holds

Big Data and AI in Safety, Regulation and Case Processing
Sep 1017:45
Conference pass

Pragmatic approaches of updates to pharmacovigilance systems for orphan drugs against the latest requirements

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Marco Sardella, Chief Pharmacovigilance Officer and Q.P.P.V. for Europe, AdienneItaly
Sep 1018:05
Conference pass

Updating signal management processes in big pharma

Signal Detection & Management and Safety in Medical Devices
Yusuf Tanrikulu, Principal P.V. Process Leader, RocheSwitzerland
Sep 1018:05
Conference pass

Risk management in the lifecycle of a product

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Peter De Veene, QPPV, Alexion PharmaceuticalsUnited Kingdom

Create your personal agenda –check the favourite icon

Sep 1108:55
Conference pass
Sep 1109:00
Conference pass

Post-Marketing Observational Studies for Pharmacovigilance in Asia: Opportunities, Issues and Management

Keynotes
Sep 1109:40
Conference pass

Database studies: Using electric medical records in Japan

Keynotes
Shinobu Uzu, Associate Executive Director, Pharmaceuticals and Medical Devices AgencyJapan
Sep 1111:10
Conference pass

Roundtables

Keynotes
Achieving effective safety standards during inspections
Lykke Bjerglund Graff, Head of Global Pharmacovigilance, LEO PharmaDenmark
Raj Bhogal, Regulatory Inspection Lead, Safety & International, R&D Quality Assurance & Compliance, Shire PharmaceuticalsUnited Kingdom
Achieving sustainability within an economic crisis
Dimitra Tsingreli, Qualified Person for Pharmacovigilance for Sigma, Kleva Pharmaceuticals SaUnited Kingdom
Establishing PV agreement in low and middle income countries
Establishing PV quality management systems
Linda Helmfors, QPPV & Head of Pharmacovigilance, Bluefish Pharmaceuticals GroupSweden
From local company to global player: Establishing a global PV system for highly specialized companies
Silvia Stoetter, Global PV Manager, Allergy TherapeuticsGermany
Andrea Maulwurf, Head of Pharmacovigilance, EU-QPPV, Allergy TherapeuticsGermany
Insights on PV systems across Russia and Eurasia
Vladimir Andrianov, Head of Scientific Studies Department, Institute of Interdisciplinary MedicineRussian Federation
Pharmacovigilance developments in Mexico
Rodrigo Ramirez, Head of Country Pharmacovigilance Mexico, Bristol-Myers SquibbUnited Kingdom
Risk minimization challenges and patient centricity
John Solomon, Head of Pharmacovigilance, SanofiUnited Kingdom
The need for simplification in PV
Giovanni Furlan, Former Sr Director, EU QPPV, SeqirusIreland
Sep 1113:20
Conference pass

Chair’s remarks

Signal Detection & Management and Safety in Medical Devices
Sep 1113:20
Conference pass

Chair’s remarks

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Pedro Lima, Regions Medical Safety Head, SanofiBrazil
Sep 1113:20
Conference pass

Chair’s remarks

Big Data and AI in Safety, Regulation and Case Processing
Tanja Peters, Deputy EU-QPPV Head PV Intelligence, Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Sep 1113:20
Conference pass

Chair’s remarks

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Jorgen Matz, Head of Global Pharmacovigilance and Drug Safety, Insud PharmaSpain
Sep 1113:25
Conference pass

Risk management for medical devices

Signal Detection & Management and Safety in Medical Devices
Lisa Benaise, Global Head,Device Safety, GaldermaSweden
Sep 1113:25
Conference pass

The evolving landscape in safety for vaccines

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Pedro Lima, Regions Medical Safety Head, SanofiBrazil
Sep 1113:25
Conference pass

MHRA Pharmacovigilance Inspection Programme: Priorities & Challenges

Big Data and AI in Safety, Regulation and Case Processing
Anna Adams, GPvP Inspector, MHRAUnited Kingdom
Sep 1113:25
Conference pass

Using RWE to support PV

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Sally Lee, Director of Pharmacodepidemiology EMEA / APAC, CelgeneUnited Kingdom
Sep 1113:45
Conference pass

Real World Evidence (RWE) to support safety evaluation of vaccines

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
  • Brief overview of the global RWE landscape applying to vaccines & why vaccines are different when it comes to RWE generation
  • Recent experience with post-marketing safety evaluation of vaccines: challenges, opportunities and successes using selected examples
  • Future perspectives
Catherine Cohet, Director, Senior Epidemiology Expert, GlaxoSmithKline VaccinesBelgium
Sep 1113:45
Conference pass

Experiences from recent regulatory inspection

Big Data and AI in Safety, Regulation and Case Processing
Janie Willadsen, QPPV, LEO Pharma A/SDenmark
Sep 1114:05
Conference pass

One size does not fill all: Challenges that are encountered in a device centric organization

Signal Detection & Management and Safety in Medical Devices
Tauqeer Karim, Vice President of Drug and Device Safety Officer, Fresenius Medical Care North AmericaUnited States
Sep 1114:05
Conference pass

Regulatory requirements for influenza vaccines: vaccine effectiveness

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Mendel Haag, Head Of Epidemiology, SeqirusNetherlands
Sep 1114:05
Conference pass

Pharmacovigilance and the role of regulatory affairs: How to achieve compliance across the business

Big Data and AI in Safety, Regulation and Case Processing
Jackie Roberts, Executive Director – Regulatory, Pharmacovigilance and Medical, Accord HealthcareUnited Kingdom
Sep 1114:05
Conference pass

RWE: Predictive Analytics to Impact Patient Safety

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
  • The use of new analytical tools applied to “big data” and gather real-time healthcare data are on the increase in the healthcare environment and have the potential to be of great value to make more informed and reliable strategic decisions earlier when it comes to protect patient safety.
  • Real-world evidence (RWE) offers great scientific and patient benefit as well as shortening phase III to accelerate the approval procedures.
  • This is mirrored by the need for pharmaceutical and biotech companies to quickly adapt their pharmacovigilance departments into cross-functional teams to confirm the expected benefit and value, often derived largely from controlled clinical studies.
Sep 1114:25
Conference pass

(No) Regulatory Drug Safety in Cell- and Tissue-based Therapies within Point-of-Care Settings

Signal Detection & Management and Safety in Medical Devices
Timo Faltus, Project Manager, University Halle Wittenberg GermanyGermany
Sep 1114:25
Conference pass

PV challenges for developing vaccines for rare diseases

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
  • Considerations about target populations, healthy vs. ill subjects
  • Benefit-risk assessment in low-incidence diseases
  • Ethical aspects for vaccine trials in special populations, such as paediatrics and elderly subjects
Sep 1114:25
Conference pass

Key updates on PRAC activities

Big Data and AI in Safety, Regulation and Case Processing
Doris Stenver, Chief Medical Officer, member of PRAC at EMA, Danish Medicines AgencyDenmark
Sep 1114:25
Conference pass

Safety information pre-launch and post-launch: providing RWE for product safety

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Sep 1115:15
Conference pass

Chair’s remarks

Signal Detection & Management and Safety in Medical Devices
Sep 1115:15
Conference pass

Chair’s remarks

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Uwe Gudat, Head of Safety, Biosimilars, Fresenius KabiSwitzerland
Sep 1115:15
Conference pass

Chair’s remarks

Big Data and AI in Safety, Regulation and Case Processing
Andrew Rut, CEO and Founder, MyMeds&MeUnited Kingdom
Sep 1115:15
Conference pass

Chair’s remarks

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Syed Zaferuddin, Deputy QPPV, JulpharSaudi Arabia
Sep 1115:20
Conference pass

Drug safety in children

Signal Detection & Management and Safety in Medical Devices
  • Specificities to take into account when performing signal detection in children
  • Importance of data entry on the results of signal detection
  • Importance of the disease
Rudi Scheerlinck, Global Head Pharmacovigilance Risk Management, Nestle Skin HealthSwitzerland
Sep 1115:20
Conference pass

Evaluating the clinical safety of a biosimilar: totality different and/or exactly the same?

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
  • The “Totality of evidence”: integrating evidence across domains
  • A Bayesian perspective on the clinical safety of candidate biosimilars
  • Reflecting on residual uncertainty: the tension between a medico-scientific and a legal perspective
Uwe Gudat, Head of Safety, Biosimilars, Fresenius KabiSwitzerland
Sep 1115:20
Conference pass

AI in case processing

Big Data and AI in Safety, Regulation and Case Processing
Diane Beck, Vice President, Head of Pharmacovigilance Services, Takeda Pharmaceutical CompanyUnited States
Sep 1115:20
Conference pass

Implementation of a PV support model in China

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Richard Wolf, Senior Director, Global Clinical Operations & Pharmacovigilance, C.S.L. Behring GmbhUnited States
Kevin Burke, Senior Case Management Lead, CSL BehringAustralia
Elva Xu, Associate Director, Medical Affairs and Pharmacovigilance, CSL BehringChina
Kevin Tynan, Consultant, PV Operations, CSL BehringUnited States
Sep 1115:40
Conference pass

What happens when pharmacovigilance fails? A Norwegian story

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Steinar Madsen, Medical Director, Norwegian Medicines Agency, NorwayNorway
Sep 1115:40
Conference pass

How structured Intake can maximise efficiencies through Case Processing

Big Data and AI in Safety, Regulation and Case Processing
Andrew Rut, CEO and Founder, MyMeds&MeUnited Kingdom
Sep 1115:50
Conference pass

The changing PV landscape: Harmonization and “right-size” PV in emerging markets

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Jabeen Ahmad, Regional Pharmacovigilance Director, EEMEA, Affiliate Vigilance Excellence, AbbVieUnited Kingdom
Sep 1116:00
Conference pass

Signal detection and risk management in generics

Signal Detection & Management and Safety in Medical Devices
Avinash Kakade, Senior Director and Head of Pharmacovigilance, CiplaMauritius
Sep 1116:00
Conference pass

Traceability of biologics and impact of safety signal detection

Risk Management/ Benefit-risk Management, Vaccine Safety and Drug Safety in Biosimilars & Biologics
Pieter Stolk, Programme Manager, LygatureNetherlands
Sep 1116:00
Conference pass

Enhanced EudraVigiliance system – industry perspectives

Big Data and AI in Safety, Regulation and Case Processing
Sep 1116:00
Conference pass

PV developments in Saudi Arabia and the Middle East

Safety in Oncology, PV Outsourcing, Real World Evidence in PV and PV in Emerging Markets
Syed Zaferuddin, Deputy QPPV, JulpharSaudi Arabia
last published: 14/Aug/18 08:35 GMT